CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich.

	Organisation	Cardior Pharmaceuticals GmbH
	Group	Novo Group (Group)
	Product	legal services
	Product 2	CDR132L (Cardior Pharmaceuticals)
	Index term	Cardior Pharmaceuticals–Novo Group: investment, 202403– acquisition for up to €1.025b incl upfront payment + milestones ANNOUNCED

CMS advises sellers of Cardior Pharmaceuticals on potential acquisition by Novo Nordisk

CMS advises the sellers of Cardior Pharmaceuticals in the potential acquisition of the company by Novo Nordisk. Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions. It is expected to happen in the second quarter of 2024.

A CMS team headed by Lead Partners Stefan-Ulrich Müller, Dr Tilman Weichert and Jörg Schrade advised the sellers of Cardior Pharmaceuticals on all legal aspects of the transaction.

Cardior Pharmaceuticals GmbH, based in Hannover, Germany, is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions.

CMS Germany

Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert, Lead Partner
Dr Michael Wangemann, Partner
Dr Kai Wallisch, Partner
Dr Thomas Mühl, Principal Counsel
Sebastian Hummel, Senior Associate
Viktoria Barthel, Senior Associate
Marielouise Emmer, Senior Associate
Dr Carl-Friedrich Thoma, Senior Associate
Dr Stefan Kühl, Senior Associate
Dr Alexander Weinhold, Senior Associate
Maria Kucher, Associate
Jonas Ohmann, Associate
Dr Josephine Doll, Associate
Dr Christian Seeburger, Associate
Sonja Schanze, Associate, all Corporate/M&A
Dr Marie-Luisa Loheide, Associate, Private Clients
Jörg Schrade, Lead Partner
Eduard Kosavtsev, Senior Associate, both Tax
Stefan Lehr, Partner, Antitrust, Competition & Trade
Stefan Lüft, Partner, IP
Dr Benedikt Forschner, Partner, Labor, Employment & Pensions
Dr Markus Kaulartz, Partner
Dr Fiona Savary, Counsel
Dr Felix Glocker, Senior Associate, all TMC
Dr Tilman Niedermaier, Partner
Susanne Schwalb, Partner, both Dispute Resolution

Press Contact

[email protected]

Record changed: 2024-04-19

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)